Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG®) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada.

The objectives of this study were to evaluate the cost-effectiveness and budget impact of octaplasLG(®) compared with fresh-frozen plasma (FFP) in all patients receiving a transfusion in Canada. A decision analytic framework was used to model acute and long-term complications that could follow plasma transfusion. Over a life time horizon, the cost with octaplasLG(®) were CA$612.91, which is CA$303.14 less than those with FFP. OctaplasLG(®) resulted in 0.021 quality adjusted life years (QALYs) gained in comparison with FFP. Because of higher efficacy and lower costs, octaplasLG(®) is expected to be the dominant treatment option over FFP in Canada.

Cost-effectiveness study comparing pharmaceutically licensed plasma for transfusion (OctaplasLG®) versus fresh frozen plasma (FFP) in critically Ill patients in the UK.

This study evaluates the cost-effectiveness of OctaplasLG® (pharmaceutically licensed plasma for transfusion) versus fresh frozen plasma (FFP) in critically ill patients in the UK using a decision-analytic approach. Transfusion with OctaplasLG® resulted in 0.03 quality adjusted life years (QALYs) and 0.03 life years saved compared with FFP. The discounted cost per life year was £949 ($1504), and the discounted cost per QALY saved was £1030 ($1632) with OctaplasLG® in the UK. Based on a higher price of £70 ($111) for OctaplasLG® versus £28.42 ($45.04) for FFP, OctaplasLG® is considered to be cost-effective at a threshold of £30,000 ($47,548) per QALY.